Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.

Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.

<p><strong>BACKGROUND:</strong> In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in response ring vaccination with the unlicensed rVSV-ZEBOV vaccine was introduced under expanded access, the first time that an Ebola vaccine has been used in an outbreak...

Bibliografske podrobnosti
Main Authors:	Gsell, P, Camacho, A, Kucharski, A, Watson, C, Bagayoko, A, Nadlaou, S, Dean, N, Diallo, A, Honora, D, Doumbia, M, Enwere, G, Higgs, E, Mauget, T, Mory, D, Riveros, X, Oumar, F, Fallah, M, Toure, A, Vicari, A, Longini, I, Edmunds, W, Henao-Restrepo, A, Kieny, M, Kéïta, S
Format:	Journal article
Jezik:	English
Izdano:	Elsevier 2017

Podobne knjige/članki

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches )
od: Watson, CH, et al.
Izdano: (2024)

rVSV-ZEBOV vaccination in people with pre-existing immunity to Ebolavirus: an open-label safety and immunogenicity study in Guinean communities affected by Ebola virus disease (l’essai proches)
od: Conall H. Watson, et al.
Izdano: (2024-11-01)

Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know?
od: Angela Huttner, et al.
Izdano: (2018-12-01)

Optimal Expression, Function, and Immunogenicity of an HIV-1 Vaccine Derived from the Approved Ebola Vaccine, rVSV-ZEBOV
od: Hiva Azizi, et al.
Izdano: (2023-05-01)

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
od: Henao-Restrepo, A, et al.
Izdano: (2016)

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV
od: Anne Rechtien, et al.
Izdano: (2017-08-01)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
od: Joan G. Tell, et al.
Izdano: (2020-12-01)

Rapid dose-dependent Natural Killer (NK) cell modulation and cytokine responses following human rVSV-ZEBOV Ebolavirus vaccination
od: Pejoski, D, et al.
Izdano: (2020)

Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
od: Huttner, A, et al.
Izdano: (2018)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
od: Selidji T Agnandji, et al.
Izdano: (2017-10-01)

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
od: Agnandji, S, et al.
Izdano: (2016)

Global blood miRNA profiling unravels early signatures of immunogenicity of Ebola vaccine rVSVΔG-ZEBOV-GP
od: Eleonora Vianello, et al.
Izdano: (2023-12-01)

Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe
od: Agnandji, S, et al.
Izdano: (2016)

Being Pregnant during the Kivu Ebola Virus Outbreak in DR Congo: The rVSV-ZEBOV Vaccine and Its Accessibility by Mothers and Infants during Humanitarian Crises and in Conflict Areas
od: David A. Schwartz
Izdano: (2020-01-01)

Pregnancy Outcomes among Women Receiving rVSVΔ-ZEBOV-GP Ebola Vaccine during the Sierra Leone Trial to Introduce a Vaccine against Ebola
od: Jennifer K. Legardy-Williams, et al.
Izdano: (2020-03-01)

Durability of immune responses induced by three leading candidate ebola vaccine regimes; rVSV ZEBOV, ChAd3 EBO Z-MVA BN-Filo and AdHu26.ZEBOV-MVA BN Filo
od: Ewer, K, et al.
Izdano: (2018)

Transcriptomic signatures induced by the Ebola virus vaccine rVSVΔG-ZEBOV-GP in adult cohorts in Europe, Africa, and North America: a molecular biomarker study
od: Vianello, E, et al.
Izdano: (2021)

Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice
od: Ian L. McWilliams, et al.
Izdano: (2019-02-01)

Lessons Learned from the Development and Roll-Out of the rVSVΔG-ZEBOV-GP <i>Zaire ebolavirus</i> Vaccine to Inform Marburg Virus and <i>Sudan ebolavirus</i> Vaccines
od: Beth-Ann G. Coller, et al.
Izdano: (2022-09-01)

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial
od: Simon Valayer, et al.
Izdano: (2025-12-01)

Recombinant Sudan virus and evaluation of humoral cross-reactivity between Ebola and Sudan virus glycoproteins after infection or rVSV-ΔG-ZEBOV-GP vaccination
od: Markus H. Kainulainen, et al.
Izdano: (2023-12-01)

Evaluation of the immunogenicity and efficacy of an rVSV vaccine against Zika virus infection in macaca nemestrina
od: Jennifer Tisoncik-Go, et al.
Izdano: (2023-02-01)

Refined innate plasma signature after rVSVΔG-ZEBOV-GP immunization is shared among adult cohorts in Europe and North America
od: Paola Andrea Martinez-Murillo, et al.
Izdano: (2024-01-01)

Development of an Integrated Continuous Manufacturing Process for the rVSV-Vectored SARS-CoV-2 Candidate Vaccine
od: Zeyu Yang, et al.
Izdano: (2023-04-01)

Development of Robust Freeze-Drying Process for Long-Term Stability of rVSV-SARS-CoV-2 Vaccine
od: MD Faizul Hussain Khan, et al.
Izdano: (2024-06-01)

The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs
od: Wenguang Cao, et al.
Izdano: (2023-06-01)

Enhanced production yields of rVSV-SARS-CoV-2 vaccine using Fibra-Cel® macrocarriers
od: Noam Cohen, et al.
Izdano: (2024-02-01)

Single dose rVSVΔG-JUNVGP vaccine protects guinea pigs against lethal Junin virus challenge
od: Teresa E. Sorvillo, et al.
Izdano: (2021-08-01)

Development and scale-up of rVSV-SARS-CoV-2 vaccine process using single use bioreactor
od: Christopher Ton, et al.
Izdano: (2023-03-01)

Understanding the Spike Protein in COVID-19 Vaccine in Recombinant Vesicular Stomatitis Virus (rVSV) Using Automated Capillary Western Blots
od: Paul F. Gillespie, et al.
Izdano: (2023-01-01)

rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment
od: Thomas P. Monath, et al.
Izdano: (2019-04-01)

UV-Inactivated rVSV-M2e-Based Influenza Vaccine Protected against the H1N1 Influenza Challenge
od: Titus Abiola Olukitibi, et al.
Izdano: (2024-05-01)

First-in-human phase I clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventive HIV-1 vaccine
od: Fuchs JD, et al.
Izdano: (2012-09-01)

Oral Immunization with rVSV Bivalent Vaccine Elicits Protective Immune Responses, Including ADCC, against Both SARS-CoV-2 and Influenza A Viruses
od: Maggie Jing Ouyang, et al.
Izdano: (2023-08-01)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
od: Amanda N. Pinski, et al.
Izdano: (2020-09-01)

Rhesus macaques show increased resistance to repeated SHIV intrarectal exposure following a heterologous regimen of rVSV vector vaccine expressing HIV antigen
od: Joseph Jelinski, et al.
Izdano: (2023-12-01)

Neutralization of SARS-CoV-2 Variants by rVSV-ΔG-Spike-Elicited Human Sera
od: Yfat Yahalom-Ronen, et al.
Izdano: (2022-02-01)

Determinants of transmission risk during the late stage of the West African Ebola epidemic
od: Robert, A, et al.
Izdano: (2019)

Development of Long-Term Stability of Enveloped rVSV Viral Vector Expressing SARS-CoV-2 Antigen Using a DOE-Guided Approach
od: MD Faizul Hussain Khan, et al.
Izdano: (2024-10-01)

Evaluation of a replication-competent VSV-SIV vaccine candidate
od: Jurgens CK, et al.
Izdano: (2012-09-01)